Evaluation of a prescreening blood donor program for prevention of perinatal transfusion-acquired cytomegalovirus (CMV) infection
Evaluation of a prescreening blood donor program for prevention of perinatal transfusion-acquired cytomegalovirus (CMV) infection
复制标题
DOI：
10.1515/jpme.1988.16.2.127
复制
发表时间：
1988
期刊：
影响因子：
10.9
通讯作者：
Nasreen A. Bhumbra;P. Lewandowski;P. Lau;Marasri Sererat-;M. Satish;G. Nankervis
中科院分区：
文献类型：
--
作者：
Nasreen A. Bhumbra;P. Lewandowski;P. Lau;Marasri Sererat-;M. Satish;G. Nankervis
本研究的目的是评估一个预先筛选的CMV血清阴性献血者组在预防输血获得性CMV感染的早产儿在围产期的有效性。招募已知CMV血清阴性状态的第0组供体，为新生儿重症监护室提供血液。127例CMV血清阴性母亲所生的低出生体重儿在输血时进行CMV抗体筛查时仍为血清阴性。在研究的初始阶段，由于技术错误或检测试剂盒的灵敏度差，22名婴儿共用了6个单位的CMV血清阳性血液。其中15名患者属于研究组。1名婴儿在4周大时死于不成熟，其余14名婴儿中有2名出现无症状CMV感染。另一名婴儿谁收到粒细胞浓缩从CMV血清阳性捐助者有症状的CMV感染。在整个24个月研究期间，ICN的血液供应充足且及时。供体血清转换率为每年0.7%。只有一个婴儿暴露于CMV感染的风险，由于供体血清转换。我们的结论是，预筛选供体程序是一个明智的和有效的方法提供CMV血清阴性血液新生儿输血治疗。
The purpose of this study was to evaluate the efficacy of a prescreened CMV seronegative blood donor group in preventing transfusion-acquired CMV infection in premature infants in the perinatal period. Group 0 donors with known CMV seronegative status were recruited to supply blood to the neonatal intensive care nurseries. One hundred and twenty-seven low birth weight infants born of CMV seronegative mothers remained seronegative when blood for transfusion was screened for CMV antibody. Twenty two infants shared six units of CMV seropositive blood due to technical errors or poor sensitivity of the test kit in the initial phase of the study. Fifteen of these patients were in the study group. One infant died of immaturity at four weeks of age and two of the remaining 14 showed asymptomatic CMV infection. Another infant who received granulocyte concentrates from CMV seropositive donors had symptomatic CMV infection. Throughout the 24 month study period, blood supply to the ICN was adequate and timely. The donor seroconversion rate was 0.7% per annum. Only one infant was exposed to the risk of CMV infection due to donor seroconversion. We conclude that the prescreening donor program is a sensible and efficient approach for providing CMV seronegative blood in neonatal transfusion therapy.